Madrigal Pharmaceuticals Competitors

Madrigal Pharmaceuticals (NASDAQ:MDGL) and Amgen (NASDAQ:AMGN) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, earnings, valuation, institutional ownership and risk.

Volatility and Risk

Madrigal Pharmaceuticals has a beta of 1.19, suggesting that its share price is 19% more volatile than the S&P 500. Comparatively, Amgen has a beta of 0.76, suggesting that its share price is 24% less volatile than the S&P 500.

Profitability

This table compares Madrigal Pharmaceuticals and Amgen's net margins, return on equity and return on assets.

Insider & Institutional Ownership

74.2% of Madrigal Pharmaceuticals shares are owned by institutional investors. Comparatively, 75.2% of Amgen shares are owned by institutional investors. 41.9% of Madrigal Pharmaceuticals shares are owned by company insiders. Comparatively, 0.4% of Amgen shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Madrigal Pharmaceuticals and Amgen, as reported by MarketBeat.

Madrigal Pharmaceuticals currently has a consensus price target of $167.60, indicating a potential upside of 34.33%. Amgen has a consensus price target of $261.0476, indicating a potential upside of 1.67%. Given Madrigal Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts plainly believe Madrigal Pharmaceuticals is more favorable than Amgen.

Earnings & Valuation

This table compares Madrigal Pharmaceuticals and Amgen's gross revenue, earnings per share (EPS) and valuation.

Amgen has higher revenue and earnings than Madrigal Pharmaceuticals. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Summary

Amgen beats Madrigal Pharmaceuticals on 9 of the 13 factors compared between the two stocks.

Madrigal Pharmaceuticals (NASDAQ:MDGL) and Gilead Sciences (NASDAQ:GILD) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, analyst recommendations, earnings, dividends, risk, institutional ownership and valuation.

Risk & Volatility

Madrigal Pharmaceuticals has a beta of 1.19, suggesting that its stock price is 19% more volatile than the S&P 500. Comparatively, Gilead Sciences has a beta of 0.51, suggesting that its stock price is 49% less volatile than the S&P 500.

Profitability

This table compares Madrigal Pharmaceuticals and Gilead Sciences' net margins, return on equity and return on assets.

Institutional & Insider Ownership

74.2% of Madrigal Pharmaceuticals shares are held by institutional investors. Comparatively, 76.4% of Gilead Sciences shares are held by institutional investors. 41.9% of Madrigal Pharmaceuticals shares are held by insiders. Comparatively, 0.1% of Gilead Sciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent recommendations for Madrigal Pharmaceuticals and Gilead Sciences, as reported by MarketBeat.com.

Madrigal Pharmaceuticals presently has a consensus price target of $167.60, indicating a potential upside of 34.33%. Gilead Sciences has a consensus price target of $97.92, indicating a potential upside of 46.43%. Given Gilead Sciences' higher probable upside, analysts clearly believe Gilead Sciences is more favorable than Madrigal Pharmaceuticals.

Earnings and Valuation

This table compares Madrigal Pharmaceuticals and Gilead Sciences' gross revenue, earnings per share (EPS) and valuation.

Gilead Sciences has higher revenue and earnings than Madrigal Pharmaceuticals. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than Gilead Sciences, indicating that it is currently the more affordable of the two stocks.

Summary

Gilead Sciences beats Madrigal Pharmaceuticals on 10 of the 13 factors compared between the two stocks.

Madrigal Pharmaceuticals (NASDAQ:MDGL) and Vertex Pharmaceuticals (NASDAQ:VRTX) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, analyst recommendations, earnings, dividends, risk, institutional ownership and valuation.

Institutional & Insider Ownership

74.2% of Madrigal Pharmaceuticals shares are held by institutional investors. Comparatively, 92.2% of Vertex Pharmaceuticals shares are held by institutional investors. 41.9% of Madrigal Pharmaceuticals shares are held by insiders. Comparatively, 0.7% of Vertex Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Risk & Volatility

Madrigal Pharmaceuticals has a beta of 1.19, suggesting that its stock price is 19% more volatile than the S&P 500. Comparatively, Vertex Pharmaceuticals has a beta of 0.79, suggesting that its stock price is 21% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent recommendations for Madrigal Pharmaceuticals and Vertex Pharmaceuticals, as reported by MarketBeat.com.

Madrigal Pharmaceuticals presently has a consensus price target of $167.60, indicating a potential upside of 34.33%. Vertex Pharmaceuticals has a consensus price target of $293.1250, indicating a potential upside of 32.98%. Given Madrigal Pharmaceuticals' higher probable upside, research analysts clearly believe Madrigal Pharmaceuticals is more favorable than Vertex Pharmaceuticals.

Profitability

This table compares Madrigal Pharmaceuticals and Vertex Pharmaceuticals' net margins, return on equity and return on assets.

Earnings and Valuation

This table compares Madrigal Pharmaceuticals and Vertex Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Vertex Pharmaceuticals has higher revenue and earnings than Madrigal Pharmaceuticals. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Vertex Pharmaceuticals beats Madrigal Pharmaceuticals on 11 of the 14 factors compared between the two stocks.

Regeneron Pharmaceuticals (NASDAQ:REGN) and Madrigal Pharmaceuticals (NASDAQ:MDGL) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, earnings, risk, dividends, institutional ownership and profitability.

Analyst Ratings

This is a breakdown of recent ratings for Regeneron Pharmaceuticals and Madrigal Pharmaceuticals, as reported by MarketBeat.

Regeneron Pharmaceuticals presently has a consensus price target of $646.2609, suggesting a potential upside of 28.58%. Madrigal Pharmaceuticals has a consensus price target of $167.60, suggesting a potential upside of 34.33%. Given Madrigal Pharmaceuticals' higher probable upside, analysts clearly believe Madrigal Pharmaceuticals is more favorable than Regeneron Pharmaceuticals.

Volatility & Risk

Regeneron Pharmaceuticals has a beta of 0.3, indicating that its share price is 70% less volatile than the S&P 500. Comparatively, Madrigal Pharmaceuticals has a beta of 1.19, indicating that its share price is 19% more volatile than the S&P 500.

Institutional and Insider Ownership

85.0% of Regeneron Pharmaceuticals shares are held by institutional investors. Comparatively, 74.2% of Madrigal Pharmaceuticals shares are held by institutional investors. 11.8% of Regeneron Pharmaceuticals shares are held by insiders. Comparatively, 41.9% of Madrigal Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Regeneron Pharmaceuticals and Madrigal Pharmaceuticals' gross revenue, earnings per share and valuation.

Regeneron Pharmaceuticals has higher revenue and earnings than Madrigal Pharmaceuticals. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Regeneron Pharmaceuticals and Madrigal Pharmaceuticals' net margins, return on equity and return on assets.

Summary

Regeneron Pharmaceuticals beats Madrigal Pharmaceuticals on 11 of the 14 factors compared between the two stocks.

Madrigal Pharmaceuticals (NASDAQ:MDGL) and Biogen (NASDAQ:BIIB) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, dividends, profitability, risk, institutional ownership and earnings.

Volatility and Risk

Madrigal Pharmaceuticals has a beta of 1.19, meaning that its stock price is 19% more volatile than the S&P 500. Comparatively, Biogen has a beta of 0.53, meaning that its stock price is 47% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current recommendations and price targets for Madrigal Pharmaceuticals and Biogen, as provided by MarketBeat.com.

Madrigal Pharmaceuticals currently has a consensus target price of $167.60, suggesting a potential upside of 34.33%. Biogen has a consensus target price of $303.5862, suggesting a potential upside of 12.12%. Given Madrigal Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts plainly believe Madrigal Pharmaceuticals is more favorable than Biogen.

Earnings and Valuation

This table compares Madrigal Pharmaceuticals and Biogen's revenue, earnings per share (EPS) and valuation.

Biogen has higher revenue and earnings than Madrigal Pharmaceuticals. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

74.2% of Madrigal Pharmaceuticals shares are held by institutional investors. Comparatively, 83.5% of Biogen shares are held by institutional investors. 41.9% of Madrigal Pharmaceuticals shares are held by company insiders. Comparatively, 0.5% of Biogen shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Madrigal Pharmaceuticals and Biogen's net margins, return on equity and return on assets.

Summary

Biogen beats Madrigal Pharmaceuticals on 9 of the 13 factors compared between the two stocks.

Madrigal Pharmaceuticals (NASDAQ:MDGL) and Alexion Pharmaceuticals (NASDAQ:ALXN) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, risk, profitability, dividends, valuation, institutional ownership and earnings.

Risk & Volatility

Madrigal Pharmaceuticals has a beta of 1.19, meaning that its stock price is 19% more volatile than the S&P 500. Comparatively, Alexion Pharmaceuticals has a beta of 1.33, meaning that its stock price is 33% more volatile than the S&P 500.

Valuation and Earnings

This table compares Madrigal Pharmaceuticals and Alexion Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Alexion Pharmaceuticals has higher revenue and earnings than Madrigal Pharmaceuticals. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than Alexion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

74.2% of Madrigal Pharmaceuticals shares are owned by institutional investors. Comparatively, 87.3% of Alexion Pharmaceuticals shares are owned by institutional investors. 41.9% of Madrigal Pharmaceuticals shares are owned by company insiders. Comparatively, 4.0% of Alexion Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of current ratings and price targets for Madrigal Pharmaceuticals and Alexion Pharmaceuticals, as provided by MarketBeat.

Madrigal Pharmaceuticals currently has a consensus target price of $167.60, suggesting a potential upside of 34.33%. Alexion Pharmaceuticals has a consensus target price of $153.8636, suggesting a potential downside of 6.00%. Given Madrigal Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Madrigal Pharmaceuticals is more favorable than Alexion Pharmaceuticals.

Profitability

This table compares Madrigal Pharmaceuticals and Alexion Pharmaceuticals' net margins, return on equity and return on assets.

Summary

Alexion Pharmaceuticals beats Madrigal Pharmaceuticals on 10 of the 14 factors compared between the two stocks.